| References: |
JNJ-31020028 bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat) and was >100-fold selective versus human Y(1), Y(4), and Y(5) receptors. JNJ-31020028 was demonstrated to be an antagonist (pK(B) = 8.04 +/- 0.13) in functional assays. JNJ-31020028 occupied Y(2) receptor binding sites (approximately 90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. For the detailed information of JNJ31020028, the solubility of JNJ31020028 in water, the solubility of JNJ31020028 in DMSO, the solubility of JNJ31020028 in PBS buffer, the animal experiment (test) of JNJ31020028, the cell expriment (test) of JNJ31020028, the in vivo, in vitro and clinical trial test of JNJ31020028, the EC50, IC50,and affinity,of JNJ31020028, For the detailed information of JNJ31020028, the solubility of JNJ31020028 in water, the solubility of JNJ31020028 in DMSO, the solubility of JNJ31020028 in PBS buffer, the animal experiment (test) of JNJ31020028, the cell expriment (test) of JNJ31020028, the in vivo, in vitro and clinical trial test of JNJ31020028, the EC50, IC50,and affinity,of JNJ31020028, Please contact DC Chemicals. |
